Stage | Sources: chemical compounds; natural products (plants, marine organisms); peptides; antibodies |
|
In vitro | Methods: high throughput screening (HTS), high content screening (HCS), surface plasmon resonance (SPR) biosensor, yeast two hybrid | Minimizing candidates |
In vivo/Ex vivo | Animal models: wild type transgenic/knockout xenograft models: in vivo study (cultured cancer cells): subcutaneously, orthotopically, systemically ex vivo study (cancer tissues from patients surgically): subcutaneously, orthotopically | Analyzing pharmacokinetics, effect and toxic side effect |
Super vitro | First-line second-line treatment model with pemetrexed-docetaxel as standard control | Accommodating to first-line and second-line treatment in clinic |
In vivo | Clinical trials Phase I: safety and dosage Phase II: efficacy and side effects Phase III: efficacy and monitoring of adverse reactions Phase IV: safety and efficacy |
|